Matthew T. David's most recent trade in CorMedix Inc was a trade of 6,515 Common Stock done at an average price of $11.2 . Disclosure was reported to the exchange on Jan. 10, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| CorMedix Inc | Matthew T. David | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.19 per share. | 10 Jan 2025 | 6,515 | 95,270 (0%) | 0% | 11.2 | 72,903 | Common Stock |
| CorMedix Inc | Matthew T. David | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 62,500 | 110,434 (0%) | 0% | 0 | Common Stock | |
| CorMedix Inc | Matthew T. David | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.22 per share. | 02 Jan 2025 | 8,648 | 101,786 (0%) | 0% | 8.2 | 71,087 | Common Stock |
| CorMedix Inc | David Matthew T. | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2024 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy Common Stock) | |
| CorMedix Inc | David T. Matthew | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2024 | 50,000 | 53,150 (0%) | 0% | 0 | Common Stock | |
| CorMedix Inc | Matthew T. David | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.47 per share. | 12 Jan 2024 | 5,216 | 47,934 (0%) | 0% | 3.5 | 18,100 | Common Stock |
| CorMedix Inc | Matthew T. David | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jan 2023 | 125,000 | 125,000 | - | - | Stock Option (Right to Buy Common Stock) |